The Modus X robotic exoscope. Image courtesy of Synaptive.
Toronto, Canada-based firm Synaptive Medical has received U.S. Food and Drug Administration clearance for Modus IR, a near-infrared fluorescence visualization module on its Modus X robotic exoscope.
The clearance bolsters the capabilities of Synaptive’s exoscope for use across all neurosurgical procedures, as well as in plastic and ENT surgery, the company said. The newly approved IR mode is used for visualizing indocyanine green (ICG) fluorescent dye. ICG causes blood to fluoresce under infrared light and is used to aid in the visualization of vessels and blood flow.
Synaptive’s Modus IR has previously been approved for clinical use in Australia, Canada, and Thailand, Synaptive noted.
